Neoplasm

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This phase II trial is testing whether the immunotherapy drug dostarlimab can eliminate the need for surgery in people with a specific type of stomach or gastroesophageal junction cancer that has a genetic marker called dMMR/MSI-H. Participants receive dostarlimab infusions, and …

This trial is testing a two-step approach for children, teens, and young adults with advanced T-cell or NK-cell lymphoma or leukemia. First, patients receive a combination of chemotherapy and immunotherapy drugs to shrink the cancer. Then, those who respond go on to receive a ste…

This early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappe…

This phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This phase II trial is testing an experimental biologic called T3011, given directly into the bladder, for people with high-risk non-muscle-invasive bladder cancer that has not responded to BCG therapy or chemotherapy. The study aims to see if this treatment can shrink or elimina…

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This study tests a drug called zotiraciclib in people with a certain type of brain tumor (glioma) that has come back after treatment. The tumor must have a specific gene mutation (IDH1 or IDH2). Participants take the drug by mouth in cycles. The goal is to see if the drug can slo…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This early-stage trial tests whether curcumin (the active ingredient in turmeric) can reverse high-grade anal precancerous lesions in people living with HIV. Participants insert curcumin capsules into the anus daily for 14 days. The main goal is to find the safest dose, not yet t…

This study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 with GATA2 mutations will receive chemotherapy or radiation before t…

This study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This trial is testing whether adding an immunotherapy drug called adebrelimab to a two-drug combination of apatinib and albumin-bound paclitaxel can help people with advanced stomach or gastroesophageal junction cancer. The study enrolls adults whose cancer has progressed after f…

This phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …

This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This early-stage trial is testing the safety and best dose of two drugs, trametinib and everolimus, given together to children and young adults whose gliomas (a type of brain tumor) have come back after previous treatment. The study aims to find the highest dose that is safe and …

This study tests alpelisib, a drug that targets a specific gene mutation (PIK3CA), in people with lymphatic malformations—abnormal growths of lymph vessels. The trial includes children and adults and compares alpelisib to a placebo to see if it can shrink the growths and ease sym…

This phase 2 trial tests whether adding two antibiotics (ciprofloxacin and metronidazole) plus aspirin to standard chemotherapy can improve outcomes for people with stage IV colorectal cancer. About 97 participants will receive either chemo alone or chemo plus the microbiome modu…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests whether a new cord blood stem cell product, Omidubicel, can improve transplant outcomes for people with severe aplastic anemia or a related bone marrow disorder. Participants receive a combination of stem cells from a family member and specially processed cord bl…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

This Phase 3 trial tests a one-time cell therapy called IMA203 for people with advanced melanoma that has not responded to prior treatment. IMA203 is made from a patient's own immune cells and is designed to target cancer cells. The study compares IMA203 to standard treatments li…

This study tests a new drug called BMS-986458, which works by breaking down a protein that helps lymphoma cells grow. It is being tested alone or with other lymphoma drugs in people whose non-Hodgkin lymphoma has returned or not responded to prior treatments. The trial aims to fi…

This phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy bu…

This early-stage trial tests a new therapy made from cord blood immune cells that are engineered to better target and attack head and neck cancer cells. Up to 33 patients with advanced disease that has not responded to standard treatments will receive these cells along with low-d…

This phase III trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy after short-course radiation can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). Participants receive eith…

This phase 2 trial is testing a new immunotherapy drug called volrustomig, combined with standard chemotherapy (FOLFIRI) and bevacizumab, in 120 people with metastatic colorectal cancer. The goal is to see if the combination is safe and helps control the cancer longer. Participan…

This study tests whether taking oral sorbitol, a common sugar alcohol, can enhance the effects of standard chemotherapy and an immunotherapy drug (tirellizumab) in people with locally advanced stomach cancer. Eighty participants will receive either sorbitol or a placebo alongside…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…

This study compares two radiation schedules for people with muscle-invasive bladder cancer who also receive chemotherapy. One group gets the usual number of radiation treatments, while the other gets fewer, higher-dose sessions. The goal is to see if the shorter course works just…

This phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…

This phase 2 trial is testing whether combining three drugs—fruquintinib, pirfenidone, and pembrolizumab—can help people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The study includes 25 participants with a specific type of tumor (…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This phase 2 trial tests whether the chemotherapy pill capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests show residual cancer DNA will take capecit…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This early study tests whether adding special cells from donated umbilical cord blood (called mesenchymal stromal cells) to the drug ruxolitinib can help control severe graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a serious complication where donor…

This trial is testing whether an experimental drug called BEBT-109, taken as a pill, can safely and effectively work alongside standard chemotherapy to treat a specific type of non-small cell lung cancer that has a particular genetic change (EGFR exon 20 insertion). The study inv…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This phase 2 trial compares pacritinib to the standard drug hydroxyurea in 66 adults with advanced proliferative chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib improves blood cell counts, reduces spleen size, and controls symptoms better than hydroxyurea…

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…

This study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…

This phase II trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 28 patients with multiple myeloma that has returned or not responded to treatment and has spread to soft tissues or organs. The goal is to see if this combo can shrink tumors or …

This trial is testing whether adding chemotherapy to radiation therapy after surgery helps prevent cervical cancer from returning in patients with certain intermediate-risk factors. Participants are adults aged 18 to 80 with early-stage cervical cancer who have had a hysterectomy…

This phase II trial is testing whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be removed by surgery. The study will enroll 25 participants with stage III or IV melanoma. The goal is to see how many …

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-phase trial tests a new treatment called attIL12-TIL for people with advanced or metastatic soft tissue and bone sarcoma. The therapy uses a patient's own tumor-fighting immune cells, modified to better target and attack cancer. The study first finds a safe dose, then …

This study tests a new way to do stem cell transplants for people with severe aplastic anemia or other bone marrow failure diseases. Doctors give a smaller number of donor white blood cells along with the stem cells to try to reduce serious side effects. Up to 120 patients aged 4…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without their cancer returning. About 478 children and young adults up to age 30 will be randomly assigned to receive either …

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This Phase 3 trial tests a device called SonoCloud-9, which uses ultrasound to temporarily open the blood-brain barrier, allowing more carboplatin chemotherapy to reach glioblastoma tumors that have returned after initial treatment. About 560 participants will be randomly assigne…

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…

This phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…

This phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…

This trial compares two weight-loss approaches—daily calorie restriction versus 5:2 intermittent fasting—in people with small kidney tumors who are being monitored rather than treated immediately. The goal is to see which program helps patients lose more weight and whether that m…

This study tests whether adding pegylated interferon alpha-2b to standard targeted immunotherapy can help people with advanced liver cancer caused by hepatitis B. The trial enrolls adults with unresectable, intermediate-to-advanced disease who are already on antiviral therapy. Pa…

This phase 3 trial is testing whether adding immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy (with or without radiation) improves survival for people aged 5 to 60 with newly diagnosed stage I or II classical Hodgkin lymphoma. About 1,875 participa…

This study tests a drug called tovorafenib (DAY101) in children and young adults (ages 6 months to 22 years) with Langerhans cell histiocytosis that has returned or not responded to treatment. The drug works by blocking enzymes that help cancer cells grow. Researchers will check …

This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This observational study is tracking 260 adults in China with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants are receiving trastuzumab deruxtecan (T-DXd) as part of their routine care, and researchers are collecting …

This phase 2 trial is testing whether adding a targeted drug called HER3-DXd to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different combinations…

This study looks at how well darolutamide (Nubeqa) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will track PSA levels to see if the cancer is con…

This trial is testing whether combining an experimental drug called IBI343 with an immunotherapy (sintilimab) and standard chemotherapy can help people with a specific type of advanced stomach or gastroesophageal junction cancer. The study focuses on patients whose tumors have a …

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab along with radiation therapy after chemotherapy can help patients with muscle invasive bladder cancer avoid bladder removal surgery. About 111 participants who responded well to initial chemotherap…

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This trial is testing two hormone-based approaches to treat early-stage, grade 2 endometrial cancer in women under 45 who wish to preserve their fertility. One approach uses a daily oral progesterone pill, while the other combines the pill with a hormone-releasing intrauterine de…

This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tests an experimental drug called JMT108 in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to check if the drug is safe and helps shrink tumors. About 188 adults who have tried other treatments without success will receive JM…

This early-stage study tests a new drug called BRiTE for safety in 18 adults with a specific type of glioblastoma (a fast-growing brain cancer). The drug is given as a continuous IV drip over 4 days each month. Only patients whose tumors have a specific genetic marker (EGFRvIII) …

This study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…

This early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look…

This phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…

This early-phase trial tests whether letrozole, a drug normally used for breast cancer, can reach and concentrate in recurrent high-grade gliomas (aggressive brain tumors). About 39 adults will take letrozole pills daily along with standard temozolomide chemotherapy. Researchers …

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This trial tests a streamlined version of radioembolization, a treatment that delivers tiny radioactive beads directly to liver tumors. The standard procedure requires extra imaging beforehand to check for radiation leakage to the lungs, which can delay treatment. For patients wi…

This study tests whether freezing cancer cells with liquid nitrogen before chemotherapy can improve outcomes for people with advanced esophageal cancer. About 40 adults will be randomly assigned to receive either the freezing treatment plus chemotherapy or chemotherapy alone. The…

This study tests the drug abemaciclib, typically used for cancer, in people with neurofibromatosis type 1 (NF1) who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if it can shrink or stabilize these tumors. Participants take…

This phase II trial compares two treatments for high-grade T1 bladder cancer that hasn't spread. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy (cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C) plus radiation.…

This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a fi…

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This trial tests a drug called selinexor combined with standard radiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) that has a specific genetic change (H3 K27M mutation). The study has two parts: first, fi…

This study tests an experimental drug called linvoseltamab in 220 people with AL amyloidosis that has returned or not improved after prior therapy. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. The trial first finds the safest dose, then…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This study tests whether adding a new drug called BEBT-209 to standard chemotherapy can shrink tumors and help people with advanced triple-negative breast cancer live longer. About 446 women aged 18 to 75 will be randomly assigned to receive either BEBT-209 plus two chemo drugs o…

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone re…

This phase 2 trial is testing whether the immunotherapy drug cemiplimab can help people with NUT carcinoma, a rare and aggressive cancer that has spread or cannot be removed by surgery. The study will enroll 15 participants and measure how long they live and whether their tumors …

This study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…

This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …

This phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This study tests whether people with large liver cancer (over 5 cm) can get their entire radioembolization treatment in a single day. Normally, planning scans and treatment are done on separate days. The procedure involves injecting tiny radioactive beads into the liver's blood s…

This study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…

This study tests a faster version of radioembolization for people with small liver cancers (5 cm or less). Normally, doctors do a pre-treatment scan to check for lung risks, but this trial skips that step for carefully selected patients. The goal is to see if the simplified appro…

This early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This early-stage trial is testing an investigational drug called BEBT-507 in adults with polycythemia vera, a condition where the body makes too many red blood cells. The study aims to find a safe dose and see if the drug can help control blood cell levels, potentially reducing t…

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the…

This phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how ma…

This Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…

This phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if …

This study tests whether a non-invasive brain stimulation technique called rTMS, given before cognitive-behavioral therapy, can help adults with cocaine use disorder quit. Thirty participants will receive either real or sham rTMS daily for 3 weeks, followed by 12 weeks of weekly …

This trial is testing whether combining two immunotherapy drugs, cemiplimab and dupilumab, can safely and effectively shrink tumors in people with early-stage, operable non-small cell lung cancer. Participants receive both drugs before their scheduled surgery, and researchers wil…

This study tests whether combining three drugs—pemigatinib, atezolizumab, and bevacizumab—can help control advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). About 25 adults whose cancer has not responded to other treatments will take part. The main goal…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take gilteritinib tablets daily in 28-day cycles. The…

This phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bor…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study tests whether a new treatment called Bria-IMT, given with an immunotherapy drug, helps people with advanced metastatic breast cancer live longer compared to standard chemotherapy. About 404 adults whose cancer has not responded to other treatments will participate. The…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…

This early study tests a new device that uses heat to remove abnormal cells in the esophagus of people with Barrett's esophagus, a condition that can lead to cancer. The study has two parts: first, a small group of people scheduled for esophagus removal surgery will help find the…

This trial asks whether removing a wider set of lymph nodes (D3) during left colon cancer surgery improves 5-year survival compared to the standard removal (D2). It enrolls about 1,381 people with adenocarcinoma located between the splenic flexure and rectosigmoid junction. Resea…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…

This phase 3 trial tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery. About 369 people with small tumors on the head, neck, hand, or shin will be randomly assigned to get either the injections or standard surgery.…

This study is for adolescents and young adults (ages not specified) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Researchers want to see if a specific combination of chemotherapy drugs plus the immunotherapy blinatumomab helps more pat…

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This early-stage trial tests a modified herpes virus (C5252) injected directly into the brain tumor cavity of 36 adults with recurrent high-grade glioma who have run out of standard options. The goal is to see if the virus is safe and can help control the disease. Participants wi…

This study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…

This phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…

This study tests whether a less invasive surgery called sentinel lymph node biopsy can replace standard neck dissection for early-stage oral cavity cancer. About 686 patients will be randomly assigned to one of the two procedures. The goal is to see if the gentler approach mainta…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…

This phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …

This phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …

This study tests the drug nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous but aggressive growth). The main goal is to see if the drug affects ovarian function, such as menstrual periods and hormone levels. Participants take nirogacestat orally,…

This study asks whether a dose-dense chemotherapy combination called CMF (cyclophosphamide, methotrexate, and fluorouracil) can be a practical alternative to the standard AC regimen (doxorubicin and cyclophosphamide) for people aged 70 and older with early-stage breast cancer. Th…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…

This study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…

This early-stage trial tests a new drug called PPM, which are tiny particles loaded with the chemotherapy drug paclitaxel and coated with a molecule (PLZ4) that helps them target bladder cancer cells. The drug is given directly into the bladder through a catheter once a week for …

This clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…

This phase I trial is testing whether giving a single, high dose of radiation (radiosurgery) before surgery can help control high grade glioma, a fast-growing brain tumor. About 28 adults with newly diagnosed or previously biopsied high grade glioma will receive radiosurgery foll…

This phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This early-phase study tests a combination of two drugs—losartan (a blood pressure medicine) and sunitinib (a cancer drug)—in people aged 10 and older with osteosarcoma (a type of bone cancer) that has returned or not responded to treatment. The main goal is to find the safest do…

This early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…

This study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma. About 45 women with early to advanced stages of the disease…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

This Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This study looks at women with breast cancer that has spread to lymph nodes under the arm, found before surgery. Normally, doctors remove many lymph nodes, which can cause arm swelling and pain. The trial tests if removing only the first few affected nodes is just as effective fo…

This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…

This study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participa…

This Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…

This study looks at two ways to protect the heart and metabolism in men with prostate cancer who are on hormone therapy (ADT). ADT can increase the risk of heart problems. The study compares time-restricted eating (a form of intermittent fasting) and two GLP-1 drugs (semaglutide …

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests a new way to deliver radiation therapy for people with diffuse glioma, a type of brain tumor. Instead of giving the same dose throughout treatment, doctors will use MRI and PET scans taken during treatment to adjust the radiation dose to target resistant areas an…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…

This study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…

This phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This early-stage study is testing whether combining two drugs—teclistamab and mezigdomide—is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 participants will receive the drugs in a specific sequence. The …

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors and improve …

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps people with sinonasal squamous cell carcinoma. About 108 participants will be randomly assigned to receive either chemo alone or chemo plus cemiplimab before th…

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if …

This study follows 138 adults in Bulgaria and Slovenia with HER2-low advanced breast cancer who are taking trastuzumab deruxtecan (T-DXd), a targeted therapy. Researchers will track how long patients go before needing a different treatment or dying. The goal is to see how well T-…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This study tests whether fecal microbiota transplantation (FMT) can reduce gut-related side effects from antibiotics in 40 adults with B-cell lymphoma who are receiving standard CAR-T cell therapy. Participants will receive FMT alongside their cancer treatment to see if it improv…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone th…

This study tests whether a continuous glucose monitor (CGM) can help people with glioblastoma, a severe brain cancer, manage their blood sugar levels and potentially live longer. High blood sugar during treatment is linked to worse outcomes, often caused by steroids. The CGM devi…

This early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…

This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…

This study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This study tests whether taking oral paclitaxel plus fruquintinib can help people with advanced stomach or gastroesophageal junction cancer after their first treatment stops working. About 150 adults will receive either the new drug combo or standard chemotherapy chosen by their …

This phase II trial is testing whether newer targeted drugs (trastuzumab emtansine and trastuzumab deruxtecan) work better than standard chemotherapy plus trastuzumab for people with HER2-positive or HER2-low salivary gland cancer that has come back, spread, or cannot be removed.…

This early-phase trial is exploring whether a radioactive drug called [211At]MABG, given in several smaller doses, is safe and tolerable for children with neuroblastoma that has relapsed or not responded to treatment. The study will include about 10 participants aged 1 year and o…

This study tests a new medicine called ersodetug for people whose tumors cause dangerously low blood sugar that standard treatments can't control. About 16 adults with insulin-producing tumors will receive the drug alongside their usual care. The main goal is to see if ersodetug …

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests whether adding enasidenib to standard treatment (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific gene mutation (IDH2). About 54 adults who have not had prior cancer therapy will be randomly assigne…

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

This study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…

This study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…

This early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…

This phase 2 trial is testing whether adding evorpacept to standard trastuzumab and chemotherapy can shrink tumors in people with metastatic HER2-positive breast cancer who have already tried the drug Enhertu. About 120 participants will receive the combination intravenously. The…

This phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…

This phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…

This Phase 2 trial tests the drug asciminib in 50 adults newly diagnosed with chronic myeloid leukemia (CML). The goal is to see if asciminib can control the disease and to check for side effects. Participants take the drug by mouth, and researchers monitor their health closely.

This study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.

This study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This trial compares two treatment approaches for men with aggressive, metastatic prostate cancer that has stopped responding to hormone therapy and docetaxel. One approach uses a combination of two chemotherapy drugs (cabazitaxel and carboplatin), while the other uses a radioacti…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…

This study tests a procedure called transarterial infusion chemotherapy (TAIC) for people with colorectal cancer that cannot be removed by surgery. Instead of giving chemo through a vein, TAIC delivers it directly to the tumor's blood supply, which may boost effectiveness and red…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. …

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This trial tests whether a 3D imaging device used during colonoscopy helps doctors find high-risk adenomas—polyps that could turn into cancer—better than the usual 2D view. Adults aged 18-75 scheduled for a diagnostic colonoscopy will be randomly assigned to either a 2D or 3D sco…

This study tests a special microscope that takes very clear, detailed pictures of cervical tissue right where the patient is being seen. The goal is to see if it can give doctors the same quality images as a standard lab test, but much faster. About 400 women in Mozambique and Br…

This study is testing a new stool DNA test (mt-sDNA 2.0) to see how well it detects colorectal cancer or advanced growths in people with Lynch syndrome, a genetic condition that raises cancer risk. Researchers will collect blood and stool samples from 950 participants and compare…

This trial is testing two experimental PET imaging tracers to see if they can show T cell activity in lung cancer tumors. People with non-small cell lung cancer who are about to have surgery after standard chemo-immunotherapy will receive two PET scans. The scans will be compared…

This study tests whether a special PET scan tracer, [18F]F-AraG, can visualize activated T-cells in tumors and healthy tissue of patients with advanced non-small cell lung cancer. The goal is to see if changes in tracer uptake during anti-PD-1 immunotherapy can predict how well t…

This study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…

This study is testing whether a combination of blood and stool biomarkers can accurately screen for cancers of the digestive tract, including stomach, esophagus, and colon. Researchers will collect blood and stool samples from 5,000 people aged 45-74 who are already scheduled for…

This study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…

This study is working on a new, non-invasive test to help rule out uterine cancer in women aged 45 and older who have abnormal bleeding. Researchers will collect samples from 4,500 women to see how well the test detects cancer and identifies benign cases. If successful, it could …

This phase 3 trial is testing a new radioactive imaging agent called 68Ga-NYM032, given as an injection before a PET/CT scan, in 365 men newly diagnosed with prostate cancer. The goal is to see if this scan can accurately detect whether the cancer has spread to pelvic lymph nodes…

This study is testing whether a blood test that measures a substance called miRNA-371 can accurately detect active testicular cancer in people who have already had their primary tumor removed. Researchers will compare the blood test results with surgical findings to see how well …

This study looks at whether a simple urine test for tumor DNA can tell which bladder cancer patients truly need a second surgery after their first tumor removal. About 196 adults with non-muscle-invasive bladder cancer will be randomly assigned to have their repeat surgery decisi…

This large study is testing whether a combined screening approach—using a blood test for DNA markers plus stool tests for hidden blood and inflammation—can catch gastrointestinal cancers earlier and save lives. Researchers will randomly assign 10,000 adults aged 45–74 to either r…

This early-stage trial is testing whether a vaccine targeting the MUC1 protein, combined with hormone therapy, can help prevent ductal carcinoma in situ (DCIS) from becoming invasive breast cancer. Fifty women with ER-positive DCIS will receive either hormone therapy alone or hor…

This trial tests whether rinsing the bladder with sterile water during surgery works as well as a chemotherapy drug (gemcitabine) placed directly into the bladder to prevent cancer from coming back. People with upper tract urothelial carcinoma who are having surgery to remove the…

This study tests whether acupuncture can reduce hot flashes in 40 men with prostate cancer who are on hormone therapy. Hot flashes are a common side effect that can disrupt sleep and daily life. Participants will receive real or sham acupuncture, and researchers will track change…

This study explores whether a normal week-long camping experience can improve the psychological well-being of children with cancer. Researchers will interview children and families before, during, and after camp to measure changes in self-esteem and social interactions. Up to 5,0…

This study compares music therapy and cognitive behavioral therapy (CBT) for reducing anxiety in people who have had cancer. 368 cancer survivors with anxiety will receive seven weekly virtual sessions of either music therapy or CBT. Researchers will track anxiety levels over 26 …

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

This trial compares two ultrasound-guided nerve block techniques for pain relief after breast cancer surgery. It aims to see which method better controls pain, reduces opioid use, and improves recovery in women undergoing a mastectomy. Participants will receive one of the two blo…

This trial tests whether a short, visual education method called PechaKucha can help people receiving chemotherapy manage their symptoms and improve their quality of life. Participants are randomly assigned to receive either this special video-based education or the standard educ…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study tests whether using a special imaging technique called Red Dichromatic Imaging (RDI) throughout the entire ESD procedure can reduce serious complications like bleeding and perforation, and shorten surgery time. About 640 adults with early stomach cancer or precancerous…

This phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…

This study tests whether a nebulizer or a standard inhaler delivers albuterol better to improve breathing in women with LAM, a rare lung disease. About 100 women with reduced lung function will stay overnight for 3 days to try each method. The goal is to see which approach opens …

This study tests whether alteplase, a drug that dissolves blood clots, can improve drainage of fluid around the lungs and reduce shortness of breath in people with cancer-related pleural effusion that is not draining well. About 30 participants will receive either alteplase or a …

This trial tests whether adding acupoint application—a herbal plaster placed on specific body points—to a standard anti-nausea drug can better control nausea and vomiting caused by chemotherapy in adults with lung cancer. Participants receiving first-line platinum-based chemother…

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …

This study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…

This study tests whether custom 3D-printed external breast prostheses improve comfort, fit, and emotional well-being for women who have had a mastectomy without reconstruction. Fifty participants will receive a personalized prosthesis made from 3D scans of their chest. The goal i…

This study looks at whether acupuncture can help young women (ages 15-40) with cancer get their periods back after chemotherapy caused them to stop. About 60 participants will receive acupuncture or usual care. Researchers will measure how many people join and finish the study, a…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…

This study tests whether two different exercise programs—one combining resistance training with cardio, the other with conditioning—have similar effects on muscle mass, fat mass, and blood pressure in women who have completed breast cancer treatment. Participants will exercise th…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This trial tests whether two physical therapies—Kinesio Taping and compression therapy—can relieve breast lymphedema, a common side effect of breast-conserving surgery and radiation that causes swelling, pain, and heaviness. About 99 women who have completed radiation and have ul…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This study tests whether a non-invasive earbud that gently stimulates a nerve in the ear can help adult survivors of childhood leukemia who have trouble sleeping. Forty participants will be randomly assigned to receive either active or sham stimulation nightly for 2 to 8 weeks. T…

This study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…

This study tests a non-invasive device called transcutaneous electrical acustimulation (TEA) in 190 elderly patients (65+) recovering from colorectal cancer surgery. The device delivers mild electrical pulses to the skin to stimulate bowel function. Participants receive TEA or a …

This study is following 3,000 adults with spine tumors (either primary or that have spread from elsewhere) who undergo surgery to relieve pressure on the spine, followed by radiation. Researchers are tracking how long patients live, whether the tumor stays under control, and how …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This observational study is looking at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in Chinese patients with advanced non-small cell lung cancer that has a specific HER2 mutation. Researchers will follow about 150 patients who are already receiving T-…

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study follows people with inherited BAP1 gene mutations, which raise the risk of mesothelioma and other cancers. Researchers will track participants over many years, collecting medical history, blood samples, and scans to understand how these mutations lead to cancer. The go…

This study tests two ways of preparing people with advanced thyroid cancer for a special PET scan that uses a radioactive form of iodine (I-124). The goal is to see which preparation method gives better information for calculating the right dose of radiation therapy. Thirty parti…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…

This study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…

This study looks at whether chemotherapy speeds up aging in the body's organs. Researchers will take blood samples from 80 women with early-stage breast cancer before and after treatment to measure markers of cellular aging. The goal is to find out if these markers can predict wh…

This study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…

This study looks at anxiety related to cancer screenings in adults with Fanconi anemia, a rare condition that raises cancer risk. Researchers will observe 20 participants during their regular screening visits, noting body language, worries, and the clinic environment. No treatmen…

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…

This study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…

This study is gathering medical information and samples from up to 5,000 people with neurosurgical conditions like brain tumors, epilepsy, and Parkinson's disease. Participants receive standard care while their data is collected for future research. No new treatments are being te…

This study follows 4700 women with high-risk gene mutations (like BRCA1/2) who choose to have a nipple-sparing mastectomy to prevent breast cancer. Researchers want to see if keeping the nipple is safe over many years, compared to traditional mastectomy that removes it. The goal …

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…

This study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study aims to find biomarkers in tumor tissue that can predict whether a patient with locally advanced rectal cancer will resist neoadjuvant chemoradiotherapy. About half of patients do not respond well to this treatment, and identifying these patients beforehand could help …

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study is testing whether a blood test that looks for cancer DNA (called a liquid biopsy) can find leftover cancer cells after surgery in people with stage III colorectal cancer. The goal is to see if this test can help doctors decide who needs additional treatment and who ca…

This study reviews 10 years of medical records from 600 adults who had thyroid surgery at Minia University Hospital. The goal is to find out which patients are most likely to develop low calcium levels after surgery, a common complication. By identifying key risk factors, doctors…

This study tests whether taking high-dose vitamin D for 6 days before photodynamic therapy (PDT) can improve the immune system's ability to fight nonmelanoma skin cancer. About 54 adults scheduled for Mohs surgery will be randomly assigned to vitamin D or placebo. Researchers wil…

This study is trying to understand why some people who get chemotherapy for cancer later develop heart issues, while others don't. Researchers will collect blood samples from 1,000 adults who have had chemotherapy, including those who had heart problems and those who didn't. By s…

This study investigates whether certain Helicobacter bacteria other than H. pylori are present in people with various stomach conditions, including chronic gastritis, precancerous changes, and gastric cancer. Researchers will analyze biopsy samples from about 150 patients to meas…

This study creates a registry for children, teens, and young adults (ages 1 month to 39 years) diagnosed with very rare solid tumors (fewer than 2 cases per million people per year). Researchers will collect medical records, tumor samples, and patient questionnaires to better und…

This phase II trial is testing whether advanced imaging techniques like DSC-MRI and PET scans can better distinguish actual tumor growth from treatment-related changes in people with newly diagnosed glioblastoma. The study will enroll 100 adults who are receiving standard treatme…

This registry tracks up to 1,500 people with triple negative breast cancer or inherited genetic mutations (like BRCA). Researchers will study how often these mutations occur, how patients respond to chemotherapy, and long-term survival. The goal is to better understand the diseas…

This study looks back at the medical records of 300 women diagnosed with lung cancer to identify common risk factors. Researchers will examine demographics, smoking history, environmental exposures, and other potential contributors. The goal is to better understand what may drive…

This study looks at how CAR T-cell therapy, a treatment for blood cancers, might affect thinking and memory in children and young adults aged 5 to 35. Researchers will test participants' memory, attention, and other thinking skills before and after treatment, over up to 3 years. …

This study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…

This study follows 600 people with GATA2 deficiency, a genetic disorder affecting the immune system and other body systems. Researchers aim to understand the full range of health problems it causes and why it affects people differently. Participants will have yearly check-ups for…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

This study is testing whether a small probe called a microdialysis catheter can be safely used during brain surgery to collect fluid samples from tumors. The goal is to measure biomarkers that could help doctors better understand and treat brain cancers like gliomas and metastati…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study looks at whether a structured recovery program called Enhanced Recovery After Surgery (ERAS) can improve outcomes for people undergoing endoscopic surgery to remove pituitary tumors. Researchers will track complications, pain, nausea, hospital stay length, and readmiss…

This study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…

This study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancers. Researchers will use leftover surgical tissue and additional samples like blood, saliva, and cheek swabs to study the…

This study is testing whether PET scans and blood tests can predict memory and thinking problems that often occur after radiation treatment for high-grade glioma. Sixteen participants will have scans and cognitive tests before, during, and after radiation. The goal is to see if t…

This study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study interviews 40 young adults aged 18-30 who use both tobacco (cigarettes or vaping) and cannabis at least weekly. Researchers want to learn how and why people start, increase, and keep using both substances together. The goal is to better understand these behaviors, not …

This study is following children and adults with olfactory neuroblastoma, a rare cancer of the nasal cavity, to learn more about how the disease behaves over time. Researchers will collect medical records, blood samples, and survey responses from 525 participants to track symptom…

This natural history study is observing up to 250 people with Smith-Lemli-Opitz syndrome and related cholesterol disorders, as well as their relatives. Researchers will track symptoms, development, and lab results over several years to find better ways to measure disease progress…

This study looks at whether a special MRI scan (mpMRI) can better monitor prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will get regular MRIs, biopsies, and blood tests over several years. The goa…

This study tests a redesigned surgical tool for removing bladder tumors. Researchers will use the device on bladder specimens from 25 patients who need their bladder removed. The goal is to see if the modified device provides better tissue samples for pathology, helping doctors a…

This study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…

This study tests a new approach called RIGHTimeCPV, designed to help children with poor-prognosis cancer and their families talk more openly with doctors about the future. Participants choose a communication companion and attend a special visit to share their preferences. The goa…

This trial compares two methods of examining colon cancer tissue after surgery: the European method, which relies solely on pathologists, and the Japanese method, which involves surgeons in finding lymph nodes. The goal is to see if the Japanese method is as accurate as the Europ…

This study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…

This study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…

This study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…

This study is testing whether a special PET/MRI scan using an investigational tracer called [18F]FMISO can help monitor how well chemotherapy works in people with HER2-positive breast cancer. The study involves 25 patients and is for imaging purposes only—it will not change their…

This study will follow 1,000 people receiving Medtronic spinal or cranial devices during routine surgery. Researchers will track outcomes like fusion success, pain relief, and device safety for up to two years. The goal is to gather real-world data on how these already-approved p…

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study monitors 202 adults in South Korea with advanced bladder cancer who are receiving the drug PADCEV (enfortumab vedotin) as part of their normal care. Researchers will track side effects and how well the cancer responds for up to a year. No new treatment is given; the go…

This study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …

This study investigates whether measuring whole-body metabolism—how the body uses energy—can reflect the metabolic changes in ovarian tumors and predict how well patients respond to chemotherapy. Researchers will measure resting metabolic rate and other metabolic markers in women…

This study is building a global patient registry to collect real-world information from people diagnosed with appendix cancer or pseudomyxoma peritonei (PMP), a rare condition where tumors spread in the abdomen. Participants and caregivers share details about their symptoms, trea…

This study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…

This study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…

This study follows 300 children and adults with chordoma, a rare bone cancer of the skull base or spine. Researchers will track how the disease progresses over time using imaging, physical exams, and surveys. The goal is to better understand chordoma's behavior to design more eff…

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study aims to better understand why some people experience dangerously low blood sugar (hypoglycemia), especially after fasting. Researchers will admit 1,500 adults to the NIH Clinical Center for controlled fasting and a series of blood tests to measure insulin and other fac…

This pilot study tests whether a special type of PET/MRI scan can monitor how triple-negative breast cancer responds to immunotherapy. Twenty patients will get three scans over their first two treatment cycles. The results won't change their care but could help design larger stud…

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their values and shares that information with their doctors. The goal is to see if using PRIME leads to treatment decis…

This study is testing whether artificial intelligence can accurately classify skin pigment, sun sensitivity (phototype), and sun damage from standard photos of the arm. Researchers will enroll 1,500 adults from diverse backgrounds, combining objective color measurements, expert a…